We analyzed the outcomes following initial relapse or refractory disease in systemic light chain 
| I N T R O D U C T I O N
Amyloidosis is a rare systemic disorder encompassing a heterogeneous group of diseases characterized by the deposition of protein fibrils in organ and tissues. 1 Immunoglobulin light chain (AL) amyloidosis is a low tumor burden plasma cell disorder, where deposition of misfolded insoluble protein fibrils (composed of monoclonal kappa or lambda light chains) in a variety of tissues progressively affects organ architecture and function. The most common organs involved are the heart, kidneys, liver, gastrointestinal tract, autonomic, and peripheral nervous system. 2 AL amyloidosis is the most common type of systemic amyloidosis with an estimated incidence of 8 to 10 cases per million individuals per year in developed countries. 3, 4 If untreated, the patients have a dismal outcome, with a median overall survival (OS) of 14 months from diagnosis. and a median OS of 3.9-5 years. [6] [7] [8] [9] [10] [11] For patients ineligible for ASCT, the combination of oral melphalan and dexamethasone (MD) is considered standard therapy. MD induces hematologic responses in 76% of patients (CR in 31%) and organ responses in 71% of the patients. 12 Among the bortezomib based therapies, the best studied regimen is cyclophosphamide, bortezomib, and dexamethasone (CyBorD) which results in an overall hematologic response rate of 60% (CR in 23%), cardiac responses in 17% and renal responses in 25% of patients. 13 Despite these advances, AL amyloidosis still remains an incurable disease and relapses remain inevitable for most patients. This necessitates multiple lines of subsequent therapy for relapsed or progressed disease. However, there is a paucity of literature describing the natural history and outcomes of relapsed or refractory patients. Therapy at relapse is often based on the previous therapeutic history including the response to therapy and toxicity, with an aim of introducing drugs with alternate mechanism of action. 14 However, there are no good studies to help make therapeutic decisions from among the multitude of options.
We performed this retrospective study to analyze the outcomes of relapsed and refractory systemic AL amyloidosis and the impact of the type of therapy, especially retreatment with the previous therapy.
| P A T I E NT S A ND M E T H O DS

| Patients
We 
| Statistical analysis
The OS was calculated from the start of second line treatment or progression mandating treatment until death from any cause or the date of last follow up. The OS curves were generated using the KaplanMeier method and differences between survival curves were tested for statistical significance using the two-sided log-rank test. 
| Outcomes
The median estimated follow up for this cohort was 69. 
| DISCUSSION
The clinical course of patients with AL amyloidosis who relapse after initial therapy is not well documented. Our findings show that these patients do well with a median survival of more than 3 years. The type of therapy at relapse did not alter the time to next therapy and OS.
Retreatment with a different drug class (as the first line treatment) at relapse significantly reduced the time to next treatment as compared to same therapy; but did not have any impact on survival.
The median time to next treatment and the median OS seen in our study of relapsed or progressed patients is better than what would be expected for newly diagnosed AL amyloidosis patients. Our prior study demonstrated that patients who received 2nd line therapy after ASCT had better outcomes as compared to the outcomes after first line treatment due to the high 1-year mortality seen in the patients with newly diagnosed systemic AL amyloidosis. The median OS of 52 months in that study was also superior to the outcomes in the present study. This discrepancy can be explained by the study design; the earlier study included a highly selected population of patients-patients who were eligible for and who survived ASCT who then relapsed; whereas, the present study evaluated patients who relapse after any therapy, thereby incorporating a potentially less selected population.This difference in survival between the 2 studies also emphasizes the benefit of including ASCT in the first line treatment of patients with AL amyloidosis. 19 Another retrospective analysis of survival among 2 cohorts of decade, the 1-year mortality has remained relatively unchanged (44%, 46%, and 43%, respectively, during 1977-1986, 1987-1996, and 1997-2006) . 20 This finding is in contrast to patients with multiple myeloma who have sequentially shorter expected overall survival with each successive therapeutic regimen. 21 The prognosis of patients with AL amyloidosis depends on the burden of the amyloid in the tissues, especially the heart. The fact that the relapsed or progressed patients survived It was also noted that second line treatment was started in 18.9% of the patients despite having non-measurable disease burden. Our previous study has shown that 14.6% of the patients with newly diagnosed AL amyloidosis had non-evaluable FLC. 22 or thalidomide (n 5 7). The overall hematological response rate was 67% among the 24 evaluable patients. Five of these 7 patients who had earlier received thalidomide achieved a hematologic response with the combination of lenalidomide and dexamethasone (4 PR and 1 CR). 27 Similarly, studies utilizing pomalidomide in combination with dexamethasone depicted its activity and tolerability at full doses (in contrast to lenalidomide) in relapsed patients including patients who were previously treated with IMiDs. 28, 29 Hence, our study opens up further options for physicians dealing with patients at relapse; the use of new treatment regimens that the patient has not been previously exposed to as well as a rechallenge with the chemotherapeutic regimen used previously.
The retrospective nature of the study limits the scope of its conclusions. However, after reviewing the current literature, to the best of our knowledge, this is the largest known series reported on this patient population. In addition, owing to the fact that AL amyloidosis is a rare disease, large phase 2 or phase 3 trials are difficult, leaving a dearth of data to use as benchmarks to plan future studies. With early and more accurate diagnosis, improved risk-stratification, introduction of novel therapies and ASCT, and advances in supportive care, the survival of patients with AL amyloidosis has improved, but relapses still remain a common consequence. Our study provides valuable data on outcomes of patients who have relapsed after first line treatment including the fact that choice of therapy at relapse does not impact survival. 
